Related Experiment Video

Updated: Sep 25, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.9K

To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years

John G Rizk1, Aashish Gupta2, Jose G Lazo3

  • 1Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland.

Seminars in Thrombosis and Hemostasis
|April 25, 2022
PubMed

Insights

COVID-19 increases blood clot risk, but therapeutic anticoagulation in critically ill patients offers no benefit and increases bleeding. Noncritically ill patients may benefit from heparin, while post-discharge anticoagulation shows promise.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Hematology

Background:

  • Coronavirus disease 2019 (COVID-19) is linked to a hypercoagulable state driven by inflammation, increasing arterial and venous thromboembolism (VTE) risk.
  • COVID-19 patients with VTE exhibit higher mortality rates compared to those without, underscoring the need for effective VTE prevention strategies.
  • High rates of microvascular and macrovascular thrombosis in COVID-19 necessitate evaluating anticoagulation strategies across different patient populations.

Approach:

  • Review of randomized control trials (RCTs) evaluating antithrombotic therapy in COVID-19 patients over the past two years.
  • Analysis of findings in critically ill hospitalized patients, noncritically ill hospitalized patients, post-discharge patients, and outpatients.
  • Inclusion of data on anticoagulation in pregnant/lactating patients and antiplatelet therapy for COVID-19.

Key Points:

  • Therapeutic dose anticoagulation in critically ill COVID-19 patients did not improve outcomes and increased bleeding compared to prophylactic doses.
  • Hospitalized noncritically ill COVID-19 patients may experience improved clinical outcomes with therapeutic doses of heparin formulations.
  • Anticoagulation with direct oral anticoagulants post-discharge may be beneficial, pending results from ongoing large RCTs.
  • Outpatients and non-hospitalized COVID-19 patients generally lack sufficient event burden for antithrombotic therapy consideration.

Conclusions:

  • Anticoagulation strategies for COVID-19 vary significantly by patient severity and setting, with critical care patients not benefiting from therapeutic doses.
  • Prophylactic anticoagulation and specific formulations like heparin may be beneficial in certain hospitalized COVID-19 patient groups.
  • Further research, including ongoing RCTs, is crucial to refine optimal antithrombotic strategies for diverse COVID-19 patient cohorts, including those post-discharge.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
34
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
948
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
55
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
49
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
49